HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
The deal gives GSK outside Greater China rights to HMPL-A830, with up to $1.2 billion in milestone payments.
8 Articles
8 Articles
HUTCHMED (China) signs licensing deal with GSK for experimental solid ...
AIM movers: Hutchmed licence deal with GSK and Futura Medical assessing potential sale
Hutchmed (China) (LON: HCM) has secured a $1.3bn licensing deal for the third programme from its ATTC with GSK. HMPL-A830 is a novel KRAS small molecule inhibitor conjugated to an EGFR antibody. This combination allows the toxic payload to be delivered directly to the tumour. The deal secures rights outside of China and related territories. […]
The clinical development of the drug will initially focus on indications related to colon cancer, pancreatic cancer and lung cancer. GSK has reached an agreement with the Chinese pharmaceutical company HUTCHMED for the rights to develop and commercialize an experimental anti-cancer drug, in a deal that could total up to approximately $1.31 billion. Specifically, GSK's subsidiary, GlaxoSmithKline Intellectual Property (No. 4) Ltd, will pay $110 m…
GSK bets $1.3B on KRAS-EGFR conjugate from HUTCHMED - European Biotechnology Magazine
GSK has licensed ex-China rights to HUTCHMED’s HMPL-A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to $1.295 billion (€1.12 billion). The preclinical asset is expected to enter the clinic this year.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
